Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey R Oxnard

Showing results (81-90 of 199) with videos related to

Pageof 20
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2024
Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue ConfirmationChristian D Rolfo, Russell W Madison, Lincoln W Pasquina, et al.
JCO Precision Oncology|July 12, 2021
High Sensitivity of Plasma Cell-Free DNA Genotyping in Cases With Evidence of Adequate Tumor ContentCatherine B Meador, Marina S D Milan, Emmy Y Hu, et al.
JCO Precision Oncology|August 17, 2022
Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin Benefit in Cisplatin-Unfit Patients With Urothelial CarcinomaRyon P Graf, Virginia Fisher, Richard S P Huang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 9, 2022
Quantifying the Value of Multigene Testing in Resected Early Stage Lung AdenocarcinomaBharathi Muthusamy, Kira Raskina, Katherine T Lofgren, et al.
JTO Clinical and Research Reports|September 30, 2021
Genomic Evolution in a Patient With Lung Adenocarcinoma With a Germline <i>EGFR</i> T790M MutationNetta Mäkinen, Meng Zhou, Meredith Bemus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung CancerGeoffrey R Oxnard, Kenneth S Thress, Ryan S Alden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2010
A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker developmentBinsheng Zhao, Geoffrey R Oxnard, Chaya S Moskowitz, et al.
The Prostate|March 14, 2022
Clinical and pathological features associated with circulating tumor DNA content in real-world patients with metastatic prostate cancerEmmanuel S Antonarakis, Marni Tierno, Virginia Fisher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2011
Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutesGeoffrey R Oxnard, Binsheng Zhao, Camelia S Sima, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2012
Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutationsNatasha Rekhtman, Paul K Paik, Maria E Arcila, et al.
Pageof 20

Showing results (81-90 of 199) with videos related to

Sort By:
Pageof 20
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2024
Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue ConfirmationChristian D Rolfo, Russell W Madison, Lincoln W Pasquina, et al.
JCO Precision Oncology|July 12, 2021
High Sensitivity of Plasma Cell-Free DNA Genotyping in Cases With Evidence of Adequate Tumor ContentCatherine B Meador, Marina S D Milan, Emmy Y Hu, et al.
JCO Precision Oncology|August 17, 2022
Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin Benefit in Cisplatin-Unfit Patients With Urothelial CarcinomaRyon P Graf, Virginia Fisher, Richard S P Huang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 9, 2022
Quantifying the Value of Multigene Testing in Resected Early Stage Lung AdenocarcinomaBharathi Muthusamy, Kira Raskina, Katherine T Lofgren, et al.
JTO Clinical and Research Reports|September 30, 2021
Genomic Evolution in a Patient With Lung Adenocarcinoma With a Germline <i>EGFR</i> T790M MutationNetta Mäkinen, Meng Zhou, Meredith Bemus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung CancerGeoffrey R Oxnard, Kenneth S Thress, Ryan S Alden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2010
A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker developmentBinsheng Zhao, Geoffrey R Oxnard, Chaya S Moskowitz, et al.
The Prostate|March 14, 2022
Clinical and pathological features associated with circulating tumor DNA content in real-world patients with metastatic prostate cancerEmmanuel S Antonarakis, Marni Tierno, Virginia Fisher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2011
Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutesGeoffrey R Oxnard, Binsheng Zhao, Camelia S Sima, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2012
Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutationsNatasha Rekhtman, Paul K Paik, Maria E Arcila, et al.
Pageof 20